Calling all early risers! Day 2 of #DPHARM2024 will feature an 8am session with Christoph Koenen of Bayer and Doug Schantz of Asklepios BioPharmaceutical, Inc. (AskBio) on Big Pharma and Biotech collaborations! Learn more about DPHARM below! 🔗 DPHARMconference.com #clinicaloperations #clinicalresearch #pharma #biotech
DPHARM: Disruptive Innovations to Modernize Clinical Research’s Post
More Relevant Posts
-
New PBOA - Pharma & Biopharma Outsourcing Association newsletter is at https://lnkd.in/eBDMvQWC, & it's got #pharma #biopharma #CMO #CDMO #outsourcing news from Pace® Analytical Services GBI Bio Lifecore Biomedical Thermo Fisher Scientific Kindeva Drug Delivery Federal Equipment Company Pfizer CentreOne AGC Biologics Enzene Biosciences Ltd & more, so go read, share & subscribe!
-
Attending is always worthwhile.
If you are a statistician, working in the biopharmaceutical industry, definitely plan to join the Regulatory Industry Statistics Workshop sponsored by ASA Biopharmaceutical Section. 🗓️ Date: September 25-27, 2024 📍 Venue: Rockville, MD Preparation is in full swing, and we can't wait to see you there! Zhiheng Xu Jianchang Lin
-
From 1998 to today, the biotech industry raised $13.3 billion in funding during the third quarter of 2024. This represents a 16% increase compared to the same period last year, although it is a 14% decrease from the $15.4 billion raised in the second quarter of 2024. #biotech #biopharma #pharma #pharmaceuticals
-
-
Curious about how Catenion contributes to the strategic selection of therapeutic targets in the pharma and biotech industry? Explore the latest whitepaper by Dr. Pascal Joly, Dr. Friederike Dündar and Dr. Christopher Buccitelli on Target Prioritization! 🚀 #Biotech #PharmaInnovation
🎯 “Which biological targets should we focus on?” This is a frequently asked question from our clients. Target prioritization is a critical early-stage decision and the foundation of the pipeline of pharmaceutical and biotech companies. Catenion has established a systematic approach to support biopharma companies to narrow down and strategically select the actionable therapeutic targets that will optimize their pipeline. Read about our methodology here: https://lnkd.in/dckT8jVq Authors: Dr. Pascal Joly, Dr. Friederike Dündar, Dr. Christopher Buccitelli ✉️ To learn more about how we can best assist you, reach out to us at: info@catenion.com #Catenion #TargetPrioritization #BiopharmaStrategy
-
BioPharma & HealthTech Competitive Strategy & Insights | Digital & AI Solutions | Gene & Cell Therapy | Vaccines
Thoughts on this? >> Agios sells rights to glioma drug to Royalty Pharma; Cargo’s $110M placement >> Comment below! >>> lqventures.com #strategy #competitiveintelligence #marketing #pharma #productmarketing #biotech #healthcare #pharmaceutical
-
We know the "Secret Ingredient" for pushing the discovery targets faster towards clinic. Write to Sarah Chatterjee to know more at sarah@dev-synthesis.com Dev-Synthesis Dev-Synthesis
Devsynthesis is attending DDC - San Diego from 1 - 4 April. Schedule meeting with Sarah Chatterjee to know why Biotech and Pharmaceutical companies collaborate with Devsynthesis. There is a "Secret Ingredient" which push the discovery projects very fast on next step. write on sarah@dev-synthesis.com for more information Devsynthesis India Pvt. Ltd.
-
-
Our end-to-end approach on target prioritization for the biopharma industry - very well summarized by Christopher, Friederike and Pascal. #Catenion #biopharma #consulting #targetID #targetprioritization
🎯 “Which biological targets should we focus on?” This is a frequently asked question from our clients. Target prioritization is a critical early-stage decision and the foundation of the pipeline of pharmaceutical and biotech companies. Catenion has established a systematic approach to support biopharma companies to narrow down and strategically select the actionable therapeutic targets that will optimize their pipeline. Read about our methodology here: https://lnkd.in/dckT8jVq Authors: Dr. Pascal Joly, Dr. Friederike Dündar, Dr. Christopher Buccitelli ✉️ To learn more about how we can best assist you, reach out to us at: info@catenion.com #Catenion #TargetPrioritization #BiopharmaStrategy
-
In case you missed it, the webinar 'Chain reaction: Navigating stability challenges in the Biopharmaceutical supply chain - from sourcing to shipping' is now available on demand 👉 https://lnkd.in/e_S4Wss Thank you to Q1 Scientific Ltd. for including us in this engaging discussion of how supply chain stakeholders can collaboratively address biopharmaceutical stability challenges.
Thank you to our panellists today for participating in our live webinar on 'Chain reaction: Navigating stability challenges in the Biopharmaceutical supply chain – from sourcing to shipping'. Moderated by Stephen Delaney, Managing Director at Q1 Scientific, our panel of experts including Aideen Glynn, Quality Manager at Q1 Scientific, Teresa C., Functional Lead, Supply Chain at APC & VLE Therapeutics, and Andrew Moss, Customer Solutions & Implementation Manager UK at Biocair delved into the intricate world of biopharmaceutical stability. Missed the live session? No worries! You can watch the recording and explore all our previous webinars on our website: https://lnkd.in/e_S4Wss #Biopharmaceutical #SupplyChain #StabilityStorage #Logistics
-
-
Early phase drug product development and manufacturing represents a critical stage in the journey from promising drug candidates to viable life-changing therapies. In the fast-paced world of drug development, the collaborative efforts between biopharmaceutical companies and Contract Development and Manufacturing Organizations (CDMOs) have become increasingly prevalent in navigating the complexities of this intricate process. Read our latest article published in PHARMAnetwork Magazine with Jerome Detreille uncovering the pivitol roles CDMOs can play in de-risking and accelerating early phase drug development, from formulation to large-scale production. https://lnkd.in/ekt5Y3Sp #CDMO #DrugDevelopment #PharmaManufacturing #LetsTalkFuture
-
-
The surge of #biotech IPOs seen in the third quarter seems to be carrying over into the fourth, as Upstream Bio and CAMP4 Therapeutics both made their trading debut. https://lnkd.in/dSY7w5eg #biotechnology #CAMP4Therapeutics #deals #pharmaceuticals #UpstreamBio
Upstream rushes to upsized IPO in double-header debut with CAMP4
We can't wait Christoph Koenen and Doug Schantz!